Results 141 to 150 of about 15,263 (254)

Modern Possibilities of Usage Dupilumab in Children

open access: yes
Dupilumab is a genetically engineered immunobiological drug that has been increasingly used in recent years to treat bronchial asthma (BA), atopic dermatitis (AD) and eosinophilic esophagitis (EE) in children.
Aishan Е. Ibaduiiaeva   +11 more
core   +1 more source

Increased Levels of Inflammatory Proteins, Including TARC/CCL17, in Skin of AD Patients During JAK Inhibitor Treatment

open access: yes
Clinical &Experimental Allergy, Volume 55, Issue 3, Page 260-263, March 2025.
Celeste M. Boesjes   +7 more
wiley   +1 more source

Trust in skincare and topical therapies in atopic dermatitis or psoriasis: a German cross‐sectional study

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Trust in therapy impacts adherence and satisfaction in chronic inflammatory skin diseases, including atopic dermatitis (AD) and psoriasis (PSO). This study assessed and compared trust in skincare and topical therapies and explored influencing factors among AD and PSO patients.
Svenja Royeck   +9 more
wiley   +1 more source

Evaluation of Small Airways Dysfunction With Dupilumab Using Airway Oscillometry in Uncontrolled Severe Asthma

open access: yes
Clinical &Experimental Allergy, Volume 55, Issue 3, Page 264-266, March 2025.
Kirsten E. Stewart   +3 more
wiley   +1 more source

Eosinophilia and Hypereosinophilia: A Practical Approach to Navigating a Broad Differential Diagnosis

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Eosinophilia, defined as an absolute eosinophil count (AEC) of ≥ 0.5 × 109/L, is a frequently encountered finding with a vast spectrum of potential underlying etiologies. Hypereosinophilia (HE) is defined as AEC > 1.5 × 109/L and may become life‐threatening when eosinophil‐induced organ damage occurs, defining the hypereosinophilic syndrome ...
Stijn Wigerinck, Peter Vandenberghe
wiley   +1 more source

Innate host defense lysozyme may help control <i>Staphylococcus aureus</i> in atopic dermatitis. [PDF]

open access: yesMicrobiol Spectr
Schlievert PM   +7 more
europepmc   +1 more source

Dupilumab Treatment in Pediatric Patients Aged 6–11 Years with Severe Atopic Dermatitis Whose Disease Is Not Adequately Controlled: A Review

open access: yes
Michael J Cork,1,2 Simon G Danby,1,2 Ana B Rossi,3 Ashish Bansal4 1Sheffield Dermatology Research, University of Sheffield, Sheffield, UK; 2Sheffield Children’s Hospital, Sheffield, UK; 3Sanofi, Cambridge, MA, USA; 4Regeneron Pharmaceuticals Inc ...
Danby SG, Bansal A, Rossi AB, Cork MJ
core  

Impact of Dupilumab and Upadacitinib Treatment on Epigenetic and Transcriptomic Alterations in Skin‐Homing T Cells of Atopic Dermatitis Patients

open access: yes
Clinical &Experimental Allergy, EarlyView.
Ahmed M. I. Elfiky   +7 more
wiley   +1 more source

Cutaneous lymphomas – an update

open access: yesHistopathology, EarlyView.
Primary cutaneous lymphomas and lymphoproliferative disorders are defined by integrated clinical, histopathological, immunophenotypic and genetic features as diagnostic criteria also in the 5th edition of the WHO classification of haematolymphoid tumors.
Werner Kempf, Christina Mitteldorf
wiley   +1 more source

Home - About - Disclaimer - Privacy